groups were fasted for 24 h, anesthetized with ether and killed to prepare liver homogenate and microsome preparations.
Preparation of Liver Homogenates and Microsomes Five milliliters of ice-cold homogenate buffer (0.25 M sucrose, 5 mM Tris, 5 mM MgCl 2 , pH 7.4) containing 1 mM mercaptoethanol (buffer A) was added per gram of tissue as soon as the liver was removed from the rats. Liver tissues were cut into small pieces and homogenized in a glass Potter homogenizer with a tight-fitting Teflon pestle (600-1000 rpm, 5 times). Homogenates were filtered through a cotton cheesecloth to remove tissue debris. Part of the filtrate was used for the homogenate fraction and the rest was centrifuged at 700ϫg for 10 min. The upper layer was recentrifuged for 10 min at 7000ϫg in buffer A with the addition of 0.1 mM EDTA (buffer B). The supernatant was collected and recentrifuged for 60 min at 105000ϫg. The pellet was collected, suspended in buffer B, and used as microsomal fraction. All the above procedures were carried out in a cold room at 4°C. The homogenates and microsomes were stored at Ϫ70°C immediately after preparation. The preparations were thawed at 4°C when used in experiments. Protein content was determined by the method of Lowry et al. 10) Cytochrome P-450 Monooxygenase Assay The content of cytochrome P-450 and NADPH-cytochrome P-450 reductase activity were determined by the method of Omura and Sato.
11)
Determination of Lipid Contents Total lipids were extracted from liver homogenates. Two milliliters of liver homogenate were mixed with 5 ml of chloroform/methanol (1 : 2, v/v) containing 0.001% butylated hydroxytoluene and 0.1 mM tocopherol by the method of Ishinaga et al. 12) Extracted total lipids were loaded onto a silicic acid column (0.5 cmϫ12 cm) and eluted with hexane and diethylether to separate neutral lipids according to the method of Rouser et al. 13) Total phospholipid contents were determined by the method of Bartlett measured as inorganic phosphorus. 14) Each phospholipid was separated from total phospholipids by two-dimensional thin-layer chromatography, first developed with chloroform/acetone/methanol/acetic acid/water (100 : 100 : 50 : 4 : 10, v/v) and then with chloroform/methanol/ acetic acid/water (180 : 150 : 30 : 100, v/v) in the vertical direction of the first development. Before the second-dimensional development, plates were dried for 1 h at room temperature under a vacuum. Separated individual phospholipids were identified by iodine vapor, scraped from the plates, and the contents of phosphorus determined by the method of Bartlett 14) with the slight modification that the colorized phosphorus was transferred into the isobutyl alcohol layer by simple centrifugation for 10 min at 3000 rpm. Contents of TG and cholesterol were determined using assay kits (Iatron Laboratories, Tokyo, Japan) after sonicating the dried neutral lipids collected on the bottom of test tubes with addition of deoxycholate 5 mM.
Determination of cAMP To investigate the effects of the exogenous addition of GRb 1 on cAMP formation, GRb 1 18 mM was added to liver homogenate (1 mg protein) prepared from the control group and incubated for 30 min at 37°C. After terminating the reaction with 80% ice-cold ethanol, cAMP was extracted from this homogenate together with liver homogenates from the saline-treated control group and from the GRb 1 -treated groups by the method of Ekanger et al. 15) and its content was determined using a cAMP radioimmunoassay kit (Amersham Life Science).
Other Methods Serum lipids and glutamate oxaloacetate transaminase (GOT) were determined using lipid and GOT assay kits (Nissui Pharmaceutical, Tokyo, Japan).
RESULTS

Effects on Activity of Microsomal Cytochrome P-450
Monooxygenase It is known that xenobiotics such as phenobarbital and hydrazine, which increase the level of cytochrome P-450 and the activity of NADPH-cytochrome P-450 reductase, enhance the level of TG in the liver. 3, 5) Because GRb 1 may be recognized as a different or the same xenobiotic as phenobarbital and hydrazine in the liver, GRb 1 was injected intraperitoneally to investigate the effect on the activity of cytochrome P-450 monooxygenase. As shown in Table 1 , the level of cytochrome P-450 and the activity of NADPH-cytochrome P-450 reductase in microsomes prepared from rat liver treated with GRb 1 10 mg were decreased compared with those in controls. It is inferred that GRb 1 has a different action from phenobarbital 3) or hydrazine 5) on microsomal monooxygenase activity and the metabolism of lipids in the liver.
Effects of GRb 1 on the Level of Lipids in Liver
In the GRb 1 10 mg groups in which cytochrome P-450 monooxygenase activity was decreased compared with controls, the levels of TG and total cholesterol (TC) were also decreased and were slightly decreased in the 1 mg group (Table 2) . However, total phospholipids (TPL), phosphatidylcholine, and phosphatidylethanolamine liver levels were increased in both GRb 1 groups (Tables 2, 3 ). The ratio of TPL to TG was higher in the liver of the GRb 1 -treated groups than that in control group. This indicates that phospholipid synthesis by the liver may be regulated by GRb 1 treatment. Since cytochrome P-450 monooxygenase regulates lipid metabolism in the liver, [3] [4] [5] 16) these results suggest that the changes in lipid contents with GRb 1 administration may be involved in the reduced activity of cytochrome P-450 monooxygenase.
Effects of GRb 1 on cAMP Level In the synthesis of TG, phosphatidate phosphohydrolase plays a stimulatory role 17) and its activity is inhibited by a catalytic subunit of cAMPdependent protein kinase. 18, 19) In our results (Tables 2, 4) , the cAMP level increased concomitantly with the decrease in TG level in the liver from the GRb 1 10 mg group. When GRb 1 10 mg/kg body weight was injected once daily for 3 d, the level of cAMP was increased as compared with that in the control group (Table 4) . When liver homogenates from the control group were incubated with exogenous GRb 1 18 mM, the level of cAMP (33.9Ϯ5.4 pmol/mg protein) was also significantly increased compared with that in controls (8.7Ϯ0.7 pmol/mg protein), and in the GRb 1 (17.0Ϯ1.7 pmol/mg protein) ( Table 4 ). These results suggest that GRb 1 may be involved directly in the formation of cAMP to inhibit the accumulation of TG in the liver.
Effects of GRb 1 on Serum Lipids Liver TG is secreted into the blood in the form of TG-rich very low-density lipoprotein (VLDL) containing various lipids such as phospholipids and cholesterol, and b-lipoprotein. The secretion of TG-rich VLDL is associated with the occurrence of hypertriglyceridemia. It is hypothesized that a decrease in liver TG levels by GRb 1 (Table 2 ) may result in an increase in blood TG levels. 20) Accordingly we investigated whether administration of GRb 1 increases or decreases the level of blood lipids containing TG. As shown in Table 5 , no specific changes in the levels of TG and b-lipoprotein in serum from the GRb 1 10 mg group were observed as compared with that in the control group. On the other hand, the levels of TC, TPL, high density lipoprotein (HDL) cholesterol, and apolipoprotein A 1 in the serum of the GRb 1 10 mg group were increased compared with those of the controls. The increase in the ratio of TG to HDL cholesterol is known to increase the risk of atherosclerosis.
21) The ratio of TG to HDL cholesterol, however, tended to decrease in the GRb 1 10 mg group (Table 5 ). Blood-free fatty acid levels increase in liver steatosis but decreased in the GRb 1 10 mg groups compared with that in controls ( Table 5) .
2) These results suggest that GRb 1 did not contribute to the release of TG from the liver and that GRb 1 might act to decrease the risk of liver steatosis.
DISCUSSION
The induction of liver microsomal cytochrome P-450 monooxygenase is involved in lipid metabolism. [3] [4] [5] 16, 22) Chemicals that increase the content of cytochrome P-450 and the activity of NADPH-cytochrome P-450 reductase stimulate the accumulation of TG in liver. GRb 1 did not induce an increase in cytochrome P-450 content and NADPH-cytochrome P-450-reductase activity, but decreased the content of cytochrome P-450 and the activity of NADPH-cytochrome P-450-reductase (Table 1) . If the reduction in cytochrome P-450 monooxygenase in the GRb 1 -treated groups was due to the proteolysis of enzyme proteins by proteolytic activation of Ca 2ϩ -dependent neutral protease in the liver, 23, 24) the Ca 2ϩ concentration should be increased and total protein content should be decreased in the liver of the GRb 1 -treated groups compared with those in the control group. In our previous report, however, it was observed that GRb 1 inhibited Ca 2ϩ accumulation in the liver 7) and liver protein content tended to increase in the GRb 1 10 mg group in the present study (Table  6 ). In particular GRb 1 significantly inhibited CCl 4 -induced Ca 2ϩ accumulation in liver homogenates and microsomes in vivo. 7) Another group reported that GRb 1 increased protein synthesis by stimulating the synthesis of mRNA and rRNA in the liver, 25) which supports the concept that GRb 1 also has elevates protein content in the liver (Table 6 ). It has been reported that detergents such as polyoxyethylene nonylphenylether (Emulgen 913) decrease the contents of liver microsomal cytochrome P-450 and serum TG levels. 26, 27) If the decrease (Table 1) in cytochrome P-450 content in the GRb 1 -treated groups resulted from the detergent-mediated effects of GRb 1 , the levels of TG and GOT in serum should be increased by liver damage or hemolysis. The serum levels of TG and GOT, however, did not change significantly (Tables  5, 6 ). These results imply that the decreases in cytochrome P-450 content and NADPH-cytochrome P-450 reductase activity (Table 1) did not result from the proteolytic activation of Ca 2ϩ -dependent neutral protease, the inhibition of protein synthesis, and detergent-mediated actions of GRb 1 . Accordingly, if the induction of cytochrome P-450 monooxygenase is associated with the accumulation of TG in the liver, 3, 5) the inhibition of cytochrome P-450 monooxygenase by GRb 1 administration (Table 1 ) may be involved in inhibition of TG formation in the liver ( Table 2 ). The ratio of TPL to TG in the GRb 1 -treated groups was higher than that in the control group (Table 2 ). This result suggests that the activity of an enzyme associated with phospholipid synthesis may be regulated by GRb 1 . That is, the decrease in TG content in the GRb 1 -treated groups could be the result of an increase in phospholipids such as phosphatidylcholine or phosphatidylethanolamine (Table 3 ). It is reported that the increase in liver TG by the microsomal cytochrome P-450 monooxygenase inducer is a result of the stimulation of microsomal phosphatidate phosphohydrolase and depletion of ATP in the liver. 3, 5) In the GRb 1 10 mg group in which liver microsomal cytochrome P-450 monooxygenase was not induced (Table 1) , we observed that GRb 1 increased the level of cAMP generated from ATP (Table 4) . It is thus suggested that GRb 1 could have a major role in the reaction of cytochrome P-450 monooxygenase to reduce TG synthesis and to increase phospholipid synthesis. It is worth noting previous results supporting our hypothesis above include: i) The inhibition of microsomal phosphatidate phosphohydrolase activity by cAMP-dependent protein kinase resulted in the reduction of TG synthesis from phosphatidic acid 18) ; and ii) GRb 1 elevated the formation of cAMP, which is known to suppress the synthesis of liver TG (Table 4) . 19, 28) In particular, the cAMP level (33.9Ϯ5.4 pmol/mg protein) was increased 3.9-fold by the addition of exogenous GRb 1 (18 mM) compared with that (8.7Ϯ0.7 pmol/mg protein) in the control group, and increased 2.0-fold compared with that (17.0Ϯ1.7 pmol/mg protein) in the GRb 1 10 mg group (Table 4) . Based on these results, it can be speculated that GRb 1 might induce a decrease in TG level via an increase of cAMP level in the liver.
If the mechanism by which GRb 1 lowers the TG level in the liver is independent on the increase in cAMP level, the cAMP level would not be increased in the GRb 1 treatment groups in which the TG level is decreased (Table 2) . However, it is not known whether the increase in cAMP level with GRb 1 administration is due to the activation of adenylate cyclase or the inhibition of cAMP-phosphodiesterase. In another experiment, it was observed that GRb 1 10 mg increased the activity of cAMP-dependent protein kinase (A-kinase) inhibited by carbon tetrachloride (CCl 4 ) (data not shown). A-kinase activity (0.65Ϯ0.1 pmol/min/mg protein) in liver homogenates from rats in the group administered CCl 4 (0.5 mg/kg body weight, i.p.) decreased compared with that (0.86Ϯ0.1 pmol/mg protein) from the control group. On the other hand, A-kinase activity in liver homogenates from the CCl 4 ϩGRb 1 10 mg treated group (0.80Ϯ0.1 pmol/min/mg protein) was increased compared with that from the CCl 4 -treated group (0.65Ϯ0.1 pmol/min/mg protein). These results suggest that GRb 1 enhances the activity of A-kinase inhibited by CCl 4 , and also that GRb 1 regulates its activation via an increase in cAMP level. Because GRb 1 decreased the level of TG in the liver (Table 2) , it can be speculated that the level of serum TG would be increased by GRb 1 administration. But the levels of TG and b-lipoprotein, a major apoprotein in VLDL, in serum from the GRb 1 10 mg group did not change compared with those in the control group (Table 5) . These results imply that GRb 1 is not involved in the secretion of TG-rich VLDL by the liver. Another major form of lipid secreted by the liver into the blood is HDL containing apolipoprotein A 1 . The activity of LDL generated by the hydrolysis of VLDL is known to be inhibited by serum HDL. The levels of HDL cholesterol and apolipoprotein A 1 were significantly increased in the GRb 1 10 mg group compared with those in the control group (Table 5) , which suggests that GRb 1 might be involved in the inhibition of hyperlipidemia. On the other hand, it is known that intracellular Ca 2ϩ accumulation in the liver is a typical phenomenon of hepatopathy. 29) In our previous report, GRb 1 inhibited CCl 4 -induced Ca 2ϩ accumulation in the liver. 7) In general, it is known that various saponins from herbal plants activate hemolysis. The ginseng saponin GRb 1 , however, does not activate hemolysis in vivo. 30) In another experiment, we found that the absorption (2.38Ϯ0.1, nϭ3) of sucrose 0.4 M-induced hemolysis indicated as absorption at 413 nm of hemoglobin (Ab 413 ) was higher than that (0.38Ϯ0.1, nϭ3) of normal erythrocytes in vitro (data not shown). GRb 1 48 mM induced little absorption of hemoglobin (0. 46Ϯ0.1, nϭ3) , and when the reaction system contained GRb 1 48 mM plus sucrose 0.4 M the Ab 413 was 0.49Ϯ0.1 (nϭ3) (data not shown). These results suggest that GRb 1 has little hemolytic activity and inhibits sucrose-induced hemolysis in vitro. Serum GOT, which is increased in hepatotoxicity or hemolysis did not change significantly in the GRb 1 10 mg group as compared with that in controls ( Table 6 ), indicating that GRb 1 does not contribute to hepatotoxicity or hemolysis in vivo. At present, we cannot confirm whether GRb 1 directly or indirectly regulates the TG level in the liver. However, when GRb 1 5 mg/kg body weight, i.v. was administered in rats, GRb 1 10 mg/ml in serum and GRb 1 0.8Ϯ0.2 mg/g in liver were observed after 24 h. 31) Accordingly, it could be inferred that GRb 1 was present in the blood or liver of rats which received intraperitoneal GRb 1 in our study and it might directly regulate the TG level in the liver.
In conclusion, GRb 1 might decrease the TG level in the liver by increasing the level of cAMP, and by decreasing the content of cytochrome P-450 and the activity of NADPH-cytochrome P-450 reductase. The levels of protein in liver homogenates and GOT in serum were determined as described in Materials and Methods.
